GomSpace delivered Q3 2026 results in line with expectations, showcasing 17% y/y revenue growth and ...
Freemelt has made significant progress in securing large contracts for its new business area Manufac...
Suominen's Q3 comparable EBITDA was slightly ahead of Vara Research consensus.
CapMan's Q3 profitability came in below our expectations, while the top line was in line with our es...
Catella's Q3 adjusted EBIT of SEK15m beat our SEK-10m, as Corporate Finance more than offset weaker ...
Redeye cut 2026–2028 adjusted EBITA by 4–10% and lower its Base Case to SEK38 (39).
Q3 adj. EBITDA of EUR 5.5m missed our estimate of EUR 6.
Rekordkvartal med god marginal för både omsättning och resultat, tack vare flera positiva faktorer i...
UPM:s plywoodverksamhet har knoppats av och noterats på Helsingforsbörsen som WISA Group.
The FINEXITY Group comfortably beat its budget after nine months of 2026.
Redeye updates its estimates and valuation after Boreo's Q3 2026 report.
Looking at the first nine months of 2026, UmweltBank AG also reported a largely stable trend...
Redeye provides its initial take on Smoltek's Q3 2026 report, which was broadly in line with our exp...
Redeye is positive about Senzime broadening the use of TetraGraph to electroconvulsive therapy (ECT)...
Q3 EBITDA (EUR 4.2m) missed SEB estimates by 6%, and consensus by 12.
Redeye provides its initial take on Acarix’s Q3 report, which came in ahead of our estimates on the ...
Suominen Q2 comparable EBITDA of EUR 5.1m came 8% above Vara Research consensus expectations.
Net sales of EUR 87m was 5% above market (LSEG) consensus but adjusted EBITDA of EUR 5.
Nekkar’s Q3 results came in soft, though largely in line with expectations, driven by a modest contr...
Redeye provides its first take on Oncopeptides’ Q3 report 2026.